Moe Alsumidaie

http://Moe%20Alsumidaie
Chief Editor
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.

Adaptive Clinical Trial Design Adaptive Trial Design AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies DOGE FDA Budget Cuts dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression

The Clinical Trial Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

Interview with Skylight Health Research Alisha Garibaldi

  • By Moe Alsumidaie
  • October 21, 2024

Previous post
Interview with Veeva’s Kenny Kong
Next post
Interview with Martin Helling Boehringer Ingelheim

Latest News

  • Semaglutide 2.4 mg Shows Greater Weight Loss Than Resmetirom in MASH 01
    News

    Semaglutide 2.4 mg Shows Greater Weight Loss Than Resmetirom in MASH

    November 7, 2026
  • ICON's FIRECREST Platform Cuts Video Production Time by 90% With New AI Engine 02
    News

    ICON’s FIRECREST Platform Cuts Video Production Time by 90% With New AI Engine

    November 6, 2026
  • Citius Oncology Presents LYMPHIR Quality-of-Life Data at EORTC Meeting 03
    News

    Citius Oncology Presents LYMPHIR Quality-of-Life Data at EORTC Meeting

    November 6, 2026
  • ATG-201 Phase I trial opens in China for B cell autoimmune diseases 04
    News

    ATG-201 Phase I trial opens in China for B cell autoimmune diseases

    November 6, 2026
  • Eton's ET-700 shows better tolerability than GALZIN but reduced efficacy in Wilson disease pilot 05
    News

    Eton’s ET-700 shows better tolerability than GALZIN but reduced efficacy in Wilson disease pilot

    November 6, 2026
  • Ivonescimab Achieves 50.7% pCR Rate in Phase II Perioperative NSCLC Study 06
    News

    Ivonescimab Achieves 50.7% pCR Rate in Phase II Perioperative NSCLC Study

    November 6, 2026
The Clinical Trial Vanguard
  • ABOUT US
  • Log In
  • Membership Account
    • Membership Billing
    • Membership Cancel
    • Membership Orders
    • Your Profile
  • Membership Checkout
    • Membership Confirmation
  • Membership Levels
  • PRIVACY POLICY
  • SUBSCRIBE
  • TERMS AND CONDITIONS OF ACCESS AND USE
Copyright © 2026 The Clinical Trial Vanguard
  • Articles
  • Conference Coverage
  • Executive Interviews
  • News
  • CliniCast

Start typing and press Enter to search

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}